Corbus Pharmaceuticals I...

4.93
-0.27 (-5.19%)
At close: Apr 03, 2025, 3:59 PM
5.18
5.07%
After-hours: Apr 03, 2025, 07:45 PM EDT

Company Description

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases.

It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases.

The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation.

It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings.

The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Corbus Pharmaceuticals Inc.
Corbus Pharmaceuticals  Inc. logo
Country United States
IPO Date Oct 27, 2014
Industry Biotechnology
Sector Healthcare
Employees 28
CEO Dr. Yuval Cohen Ph.D.

Contact Details

Address:
500 River Ridge Drive
Norwood, Massachusetts
United States
Website https://www.corbuspharma.com

Stock Details

Ticker Symbol CRBP
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001595097
CUSIP Number 21833P103
ISIN Number US21833P3010
Employer ID 46-4348039
SIC Code 2834

Key Executives

Name Position
Dr. Yuval Cohen Ph.D. Chief Executive Officer & Director
Dr. Ian Hodgson Chief Operating Officer
Christina Bertsch Vice President of Human Resources
Dr. Dominic Smethurst M.A., M.D. Chief Medical Officer

Latest SEC Filings

Date Type Title
Apr 01, 2025 ARS Filing
Apr 01, 2025 DEFA14A Filing
Apr 01, 2025 DEF 14A Filing
Mar 21, 2025 8-K Current Report
Mar 18, 2025 3 Filing
Mar 18, 2025 8-K Current Report
Mar 11, 2025 10-K Annual Report
Mar 11, 2025 8-K Current Report
Mar 07, 2025 4 Filing
Feb 18, 2025 4 Filing